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Background: Whether high-dose clopidogrel may improve early clinical outcome has been debated. We compared the efficacy and safety of high-
dose (600mg) vs. moderate-dose (300mg) clopidogrel loading in patients with Non-ST-elevation acute coronary syndrome (ACS) or stable angina 
who receive drug-eluting stents (DES), and clarified treatment effects in several subgroups.
Methods: Among 2645 patients enrolled in the ZEST trial, we evaluated 1421 patients with eligible data regarding clopidogrel loading dose and 
who not on chronic clopidogrel therapy: 300mg (N=1226) or 600mg (N=195) loading. Primary outcome was a incidence of major adverse cardiac 
event(MACE: death, myocardial infarction [MI], urgent-revascularization) at 30 day. We evaluated treatment effect in several subgroups according to 
age, sex, and the presence or absence of diabetes, ACS, acute MI, multivessel disease, long lesion, or small vessel.
Results: At 30 days, MACE occurred 7.0% in 300mg group and 4.6% in 600mg group (p=0.22). After multivariable-adjustment, there was no 
difference of risk of MACE between the groups(odd ratio 0.86, 95% CI 0.41-1.80, p=0.69). This trend was consistent in several subgroups(figure). 
Additionally, the incidence of bleeding was similar in 300mg and 600mg group(1.1% vs. 0%, p=0.24)
Conclusions: In patients receiving DES, high-dose clopiodgrel loading did not significantly reduce early MACE 
compared with moderate-dose loading. Our findings should be refuted or confirmed in large randomized trial.
